Lyell Immunopharma Inc (NASDAQ:LYEL)’s traded shares stood at 1.35 million during the last session, with the company’s beta value hitting -0.41.The LYEL share’s 52-week high remains $3.26, putting it -196.36% down since that peak but still an impressive 22.73% since price per share fell to its 52-week low of $0.85. The company has a valuation of $307.14M, with an average of 1.34 million shares in intraday trading volume over the past 10 days and average of 1.09 million shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for Lyell Immunopharma Inc (LYEL), translating to a mean rating of 3.33. Of 3 analyst(s) looking at the stock, 0 analyst(s) give LYEL a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 0 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.18.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lyell Immunopharma Inc (NASDAQ:LYEL) trade information
The 5-day price performance for the stock is -9.84%, and -6.78% over 30 days. With these gigs, the year-to-date price performance is -43.30%. Short interest in Lyell Immunopharma Inc (NASDAQ:LYEL) saw shorts transact 11.14 million shares and set a 7.69 days time to cover.
The extremes give us $1 and $12 for target low and target high price respectively. As such, LYEL has been trading -990.91% off suggested target high and 9.09% from its likely low.
Lyell Immunopharma Inc (LYEL) estimates and forecasts
Looking at statistics comparing Lyell Immunopharma Inc share performance against respective industry, we note that the company has underperformed competitors. Lyell Immunopharma Inc (LYEL) shares are -59.85% down over the last 6 months, with its year-to-date growth rate lower than industry average at 13.98% against 16.20%. Revenue is forecast to grow 8.34% this quarter before jumping 20.83% for the next one. The rating firms project that company’s revenue will grow 1,829.23% compared to the previous financial year.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -15.28% for the past 5-year period. While 2024 is set for a 14.52% return in earnings, projections for the next 5 years are at -7.90% annually.
LYEL Dividends
Lyell Immunopharma Inc has its next earnings report out on 2024-Nov-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Lyell Immunopharma Inc (NASDAQ:LYEL)’s Major holders
Lyell Immunopharma Inc insiders hold 14.06% of total outstanding shares, with institutional holders owning 61.54% of the shares at 71.61% float percentage. In total, 61.54% institutions holds shares in the company, led by MWG MANAGEMENT LTD.. As of 2024-06-30, the company held over 20.16 million shares (or 7.9301% of shares), all amounting to roughly $29.24 million.
The next major institution holding the largest number of shares is ORLAND PROPERTIES LTD with 15.09 million shares, or about 5.9366% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $21.89 million.
